摘要
Abstract
Objective To compare the efficacy between bortezomib plus pirarubicin and dexamethasone ( BAD ) and vincristine plus piraru-bicin and dexamethasone ( VAD ) as the initial therapy for treating newly diagnosed multiple myeloma ( MM ) . Methods 32 patients with MM in our hospital were randomly divided into two groups. The BAD group ( 14 cases ) were treated with bortezomib 1. 3 mg/ ( m2 · d ) by intravenous injection on 1, 4, 8, 11 d, dexamethasone 40 mg/d by intravenous infusion on 1-4 d and pirarubicin 10 mg/ (m2·d) by intravenous injection on 1-4 d for 3 weeks as 1 course of treatment. The VAD group (18 cases) were treated by vincristine 0. 4 mg/(m2·d) by intravenous injection on 1-4 d, pirarubicin 10 mg/ ( m2 · d ) by intravenous injection on 1-4 d and dexamethasone 40 mg/d twice daily as oral administration on 1-4 d for 4 weeks as 1 course of treatment. Results :The overall response ( OR ) rate was 78. 57% in the BAD group and 61. 11% in the VAD group with no statistically significant difference ( P>0. 05 ) . But the complete remission ( CR ) plus the near-CR ( nCR ) rate in the BAD group was 57. 14%, which was significantly higher than 16. 67% in the VAD group;the dif-ference showed the statistical significance ( P<0. 05 ) , moreover without increasing the occurrence rate of adverse reactions. Conclusion Although the OR rate in the BAD scheme for the initial therapy of MM has no obvious difference compared with the traditional chemotherapy scheme, but CR+nCR is significantly higher with less and tolerable adverse reactions, and can be safely used in the pa-tients with renal dysfunction.关键词
多发性骨髓瘤/硼替佐米/地塞米松/吡柔比星/不良反应Key words
multiple myeloma/bortezomib/dexamethasone/pirarubicin/adverse reactions分类
医药卫生
